A M Menzies1,2, D B Johnson3, S Ramanujam1, V G Atkinson4, A N M Wong5, J J Park6, J L McQuade7, A N Shoushtari8, K K Tsai9, Z Eroglu10, O Klein11, J C Hassel12, J A Sosman3, A Guminski1,2, R J Sullivan13, A Ribas14, M S Carlino1,6, M A Davies7, S K Sandhu5, G V Long1,2. 1. Melanoma Institute Australia and The University of Sydney, Sydney, Australia. 2. Royal North Shore and Mater Hospitals, Sydney, Australia. 3. Vanderbilt University Medical Center, Nashville, USA. 4. Princess Alexandra Hospital, Greenslopes Hospital and University of Queensland, Brisbane, Australia. 5. Peter MacCallum Cancer Centre, Melbourne, Australia. 6. Crown Princess Mary Cancer Centre Westmead, Sydney, Australia. 7. The University of Texas MD Anderson Cancer Center, Houston, USA. 8. Memorial Sloan Kettering Cancer Center, New York, USA. 9. Department of Medical Oncology, University of California San Francisco, San Francisco, USA. 10. Department of Medical Oncology, Moffitt Cancer Centre, Tampa, USA. 11. Department of Medical Oncology, Olivia Newton-John Cancer Centre & Cancer Research Institute, Austin Health, Melbourne, Australia. 12. Department of Dermatology, Heidelberg University, Heidelberg, Germany. 13. Massachusetts General Hospital Cancer Center, Boston, USA. 14. Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, USA.
Abstract
Background: Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant preexisting autoimmune disorders (ADs) and only one has included patients with immune-related adverse events (irAEs) with ipilimumab. We sought to explore the safety and efficacy of anti-PD-1 in such patients. Patients and methods: Patients with advanced melanoma and preexisting ADs and/or major immune-related adverse events (irAEs) with ipilimumab (requiring systemic immunosuppression) that were treated with anti-PD-1 between 1 July 2012 and 30 September 2015 were retrospectively identified. Results: One hundred and nineteen patients from 13 academic tertiary referral centers were treated with anti-PD-1. In patients with preexisting AD (N = 52), the response rate was 33%. 20 (38%) patients had a flare of AD requiring immunosuppression, including 7/13 with rheumatoid arthritis, 3/3 with polymyalgia rheumatica, 2/2 with Sjogren's syndrome, 2/2 with immune thrombocytopaenic purpura and 3/8 with psoriasis. No patients with gastrointestinal (N = 6) or neurological disorders (N = 5) flared. Only 2 (4%) patients discontinued treatment due to flare, but 15 (29%) developed other irAEs and 4 (8%) discontinued treatment. In patients with prior ipilimumab irAEs requiring immunosuppression (N = 67) the response rate was 40%. Two (3%) patients had a recurrence of the same ipilimumab irAEs, but 23 (34%) developed new irAEs (14, 21% grade 3-4) and 8 (12%) discontinued treatment. There were no treatment-related deaths. Conclusions: In melanoma patients with preexisting ADs or major irAEs with ipilimumab, anti-PD-1 induced relatively frequent immune toxicities, but these were often mild, easily managed and did not necessitate discontinuation of therapy, and a significant proportion of patients achieved clinical responses. The results support that anti-PD-1 can be administered safely and can achieve clinical benefit in patients with preexisting ADs or prior major irAEs with ipilimumab.
Background: Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant preexisting autoimmune disorders (ADs) and only one has included patients with immune-related adverse events (irAEs) with ipilimumab. We sought to explore the safety and efficacy of anti-PD-1 in such patients. Patients and methods: Patients with advanced melanoma and preexisting ADs and/or major immune-related adverse events (irAEs) with ipilimumab (requiring systemic immunosuppression) that were treated with anti-PD-1 between 1 July 2012 and 30 September 2015 were retrospectively identified. Results: One hundred and nineteen patients from 13 academic tertiary referral centers were treated with anti-PD-1. In patients with preexisting AD (N = 52), the response rate was 33%. 20 (38%) patients had a flare of AD requiring immunosuppression, including 7/13 with rheumatoid arthritis, 3/3 with polymyalgia rheumatica, 2/2 with Sjogren's syndrome, 2/2 with immune thrombocytopaenic purpura and 3/8 with psoriasis. No patients with gastrointestinal (N = 6) or neurological disorders (N = 5) flared. Only 2 (4%) patients discontinued treatment due to flare, but 15 (29%) developed other irAEs and 4 (8%) discontinued treatment. In patients with prior ipilimumab irAEs requiring immunosuppression (N = 67) the response rate was 40%. Two (3%) patients had a recurrence of the same ipilimumab irAEs, but 23 (34%) developed new irAEs (14, 21% grade 3-4) and 8 (12%) discontinued treatment. There were no treatment-related deaths. Conclusions: In melanomapatients with preexisting ADs or major irAEs with ipilimumab, anti-PD-1 induced relatively frequent immune toxicities, but these were often mild, easily managed and did not necessitate discontinuation of therapy, and a significant proportion of patients achieved clinical responses. The results support that anti-PD-1 can be administered safely and can achieve clinical benefit in patients with preexisting ADs or prior major irAEs with ipilimumab.
Authors: Kaustav P Shah; Haocan Song; Fei Ye; Javid J Moslehi; Justin M Balko; Joe-Elie Salem; Douglas B Johnson Journal: Cancer Immunol Res Date: 2020-04-29 Impact factor: 11.151
Authors: Hyun-Sung Lee; Hee-Jin Jang; Rohan Shah; David Yoon; Masatsugu Hamaji; Ori Wald; Ju-Seog Lee; David J Sugarbaker; Bryan M Burt Journal: Clin Cancer Res Date: 2017-04-11 Impact factor: 12.531
Authors: Steven M Bair; Lauren E Strelec; Tatyana A Feldman; Gulrayz Ahmed; Philippe Armand; Nirav N Shah; Arun N Singavi; Nishitha Reddy; Nadia Khan; Charalambos Andreadis; Khoan Vu; Scott F Huntington; Smith Giri; Chaitra Ujjani; Christina Howlett; Malik Faheem; Matthew R Youngman; Sunita D Nasta; Daniel J Landsburg; Stephen J Schuster; Jakub Svoboda Journal: Oncologist Date: 2018-12-19
Authors: Christina S Baik; Eric H Rubin; Patrick M Forde; Janice M Mehnert; Deborah Collyar; Marcus O Butler; Erica L Dixon; Laura Q M Chow Journal: Clin Cancer Res Date: 2017-09-01 Impact factor: 12.531
Authors: Kristen E Pauken; Michael Dougan; Noel R Rose; Andrew H Lichtman; Arlene H Sharpe Journal: Trends Immunol Date: 2019-04-30 Impact factor: 16.687